Assembly Biosciences Stock Performance
| ASMB Stock | USD 26.85 1.39 4.92% |
The firm shows a Beta (market volatility) of 1.03, which signifies a somewhat significant risk relative to the market. Assembly Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Assembly Biosciences is expected to follow. At this point, Assembly Biosciences has a negative expected return of -0.17%. Please make sure to confirm Assembly Biosciences' kurtosis, and the relationship between the treynor ratio and day typical price , to decide if Assembly Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Assembly Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's primary indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return 7.09 | Five Day Return 7.62 | Year To Date Return (16.30) | Ten Year Return (54.66) | All Time Return (92.53) |
Last Split Factor 1:12 | Last Split Date 2024-02-12 |
1 | Marylands new proposed congressional map faces criticism | 01/22/2026 |
2 | Arellano Under Trump, the bootlickers have come out in force. Minneapolis cements it | 01/26/2026 |
3 | Frances National Assembly adopts expenditure section of 2026 state budget despite censure motions | 01/28/2026 |
4 | Reallusion Expands to a Complete Human-Centric Simulation Solution | 01/29/2026 |
5 | This 110 standing desk deal from our favorite maker fixes the biggest design flaw found on almost every other budget model | 01/30/2026 |
6 | New bill aims to make California FAIR Plan cover all insurance risks, not just fire | 02/02/2026 |
| Begin Period Cash Flow | 19.8 M | |
| Total Cashflows From Investing Activities | 40.2 M |
Assembly Biosciences Relative Risk vs. Return Landscape
If you would invest 3,121 in Assembly Biosciences on November 6, 2025 and sell it today you would lose (436.00) from holding Assembly Biosciences or give up 13.97% of portfolio value over 90 days. Assembly Biosciences is currently does not generate positive expected returns and assumes 3.8763% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Assembly, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Assembly Biosciences Target Price Odds to finish over Current Price
The tendency of Assembly Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 26.85 | 90 days | 26.85 | over 95.61 |
Based on a normal probability distribution, the odds of Assembly Biosciences to move above the current price in 90 days from now is over 95.61 (This Assembly Biosciences probability density function shows the probability of Assembly Stock to fall within a particular range of prices over 90 days) .
Assembly Biosciences Price Density |
| Price |
Predictive Modules for Assembly Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Assembly Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Assembly Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Assembly Biosciences is not an exception. The market had few large corrections towards the Assembly Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Assembly Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Assembly Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.13 | |
β | Beta against Dow Jones | 1.03 | |
σ | Overall volatility | 3.41 | |
Ir | Information ratio | -0.03 |
Assembly Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Assembly Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Assembly Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Assembly Biosciences generated a negative expected return over the last 90 days | |
| Assembly Biosciences has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 28.52 M. Net Loss for the year was (40.18 M) with loss before overhead, payroll, taxes, and interest of (24.65 M). | |
| Assembly Biosciences currently holds about 116.69 M in cash with (51.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.41. | |
| Assembly Biosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: New bill aims to make California FAIR Plan cover all insurance risks, not just fire |
Assembly Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Assembly Stock often depends not only on the future outlook of the current and potential Assembly Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Assembly Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 6 M | |
| Cash And Short Term Investments | 112.1 M |
Assembly Biosciences Fundamentals Growth
Assembly Stock prices reflect investors' perceptions of the future prospects and financial health of Assembly Biosciences, and Assembly Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Assembly Stock performance.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (1.01) % | ||||
| Current Valuation | 176.86 M | ||||
| Shares Outstanding | 15.82 M | ||||
| Price To Earning | (10.58) X | ||||
| Price To Book | 2.23 X | ||||
| Price To Sales | 11.21 X | ||||
| Revenue | 28.52 M | ||||
| Gross Profit | (24.65 M) | ||||
| EBITDA | (45.29 M) | ||||
| Net Income | (40.18 M) | ||||
| Cash And Equivalents | 116.69 M | ||||
| Cash Per Share | 2.41 X | ||||
| Total Debt | 3.09 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 8.31 X | ||||
| Book Value Per Share | 11.55 X | ||||
| Cash Flow From Operations | (51.12 M) | ||||
| Earnings Per Share | (4.60) X | ||||
| Market Capitalization | 417.1 M | ||||
| Total Asset | 119.17 M | ||||
| Retained Earnings | (825.92 M) | ||||
| Working Capital | 67.7 M | ||||
| Current Asset | 68.37 M | ||||
| Current Liabilities | 3.4 M | ||||
About Assembly Biosciences Performance
By analyzing Assembly Biosciences' fundamental ratios, stakeholders can gain valuable insights into Assembly Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Assembly Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Assembly Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (21.48) | (22.55) | |
| Return On Tangible Assets | (0.30) | (0.32) | |
| Return On Capital Employed | (0.73) | (0.77) | |
| Return On Assets | (0.30) | (0.32) | |
| Return On Equity | (1.39) | (1.32) |
Things to note about Assembly Biosciences performance evaluation
Checking the ongoing alerts about Assembly Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Assembly Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Assembly Biosciences generated a negative expected return over the last 90 days | |
| Assembly Biosciences has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 28.52 M. Net Loss for the year was (40.18 M) with loss before overhead, payroll, taxes, and interest of (24.65 M). | |
| Assembly Biosciences currently holds about 116.69 M in cash with (51.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.41. | |
| Assembly Biosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: New bill aims to make California FAIR Plan cover all insurance risks, not just fire |
- Analyzing Assembly Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Assembly Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Assembly Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Assembly Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Assembly Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Assembly Biosciences' stock. These opinions can provide insight into Assembly Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Assembly Stock analysis
When running Assembly Biosciences' price analysis, check to measure Assembly Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assembly Biosciences is operating at the current time. Most of Assembly Biosciences' value examination focuses on studying past and present price action to predict the probability of Assembly Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assembly Biosciences' price. Additionally, you may evaluate how the addition of Assembly Biosciences to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |